Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Li, Chuanxing
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. [electronic resource] - Journal of cancer research and clinical oncology Nov 2010 - 1633-40 p. digital
Publication Type: Journal Article
1432-1335
10.1007/s00432-010-0821-z doi
Adult
Antineoplastic Agents--therapeutic use
Benzenesulfonates--therapeutic use
Brachytherapy--methods
Carcinoma, Hepatocellular--surgery
Cause of Death
Combined Modality Therapy
Follow-Up Studies
Humans
Iodine Radioisotopes--therapeutic use
Liver Neoplasms--surgery
Liver Transplantation
Lung Neoplasms--drug therapy
Male
Middle Aged
Neoplasm Metastasis--drug therapy
Niacinamide--analogs & derivatives
Patient Care Planning
Phenylurea Compounds
Pyridines--therapeutic use
Sorafenib
Survival Rate
Time Factors
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma. [electronic resource] - Journal of cancer research and clinical oncology Nov 2010 - 1633-40 p. digital
Publication Type: Journal Article
1432-1335
10.1007/s00432-010-0821-z doi
Adult
Antineoplastic Agents--therapeutic use
Benzenesulfonates--therapeutic use
Brachytherapy--methods
Carcinoma, Hepatocellular--surgery
Cause of Death
Combined Modality Therapy
Follow-Up Studies
Humans
Iodine Radioisotopes--therapeutic use
Liver Neoplasms--surgery
Liver Transplantation
Lung Neoplasms--drug therapy
Male
Middle Aged
Neoplasm Metastasis--drug therapy
Niacinamide--analogs & derivatives
Patient Care Planning
Phenylurea Compounds
Pyridines--therapeutic use
Sorafenib
Survival Rate
Time Factors